 Provention Bio Inc NASDAQ: PRVB has announced interim results from the PROVENT Phase 1 trial of PRV-101. PRV-101 is a polyvalent inactivated coxsackievirus B CVB vaccine candidate targeting all five key CVB strains associated with type 1 diabetes T1D autoimmunity. 